Catalyst Calendar

Wed, Aug 5, 2026

1 updates

4:01 PM

Xencor Reports Second Quarter 2026 Financial Results

-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week

Presentation / Abstract • Phase 1ESMO oral presentation Fri, Oct 23, 2026xencor.com

Wed, Jul 29, 2026

1 updates

XNCR

4:01 PM

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- -- Ex- U.S. royalties remain unchanged -- PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2026-- Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered

xencor.com

Fri, Jul 17, 2026

1 updates

XNCR

9:11 AM

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- PASADENA, Calif. --(BUSINESS WIRE)--Jul. 17, 2026-- Xencor, Inc.

Presentation / Abstract • Phase 1ESMO abstract release Sun, Oct 18, 2026, 3:05 PM PDTxencor.com